首个国产IL-17A/F双靶点抑制剂获批,这一40年来“有研究无产品”的靶点迎临床突破|掘金创新药

每日经济新闻
Sep 02

半月临床试验动向  根据医药魔方提供的数据,8月15日至8月28日,国家药品监督管理局药品审评中心(CDE)共披露195条创新药临床试验登记信息,其中53条为Ⅱ期及以上的关键临床试验。   8月15日至8月28日,国家药品监督管理局批准8款创新药上市。 ""  前沿洞察 首个国产IL-17A/F双靶点抑制剂获批,丽珠集团杀入银屑病“红海”  8月25日,丽珠集团子公司珠海市丽珠单抗生物技术...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10